



Supplementary Fig. 4. Characteristics of the *HOXD9* high group. (A, B) Associations between *HOXD9* and clinical factors, including tumor size and extrathyroidal extension (ETE). (C) Nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) signaling from gene set enrichment analysis in the *HOXD9*-high group. (D) Transcription factors such as transcription factor 3 (TCF3) and enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) regulate the expression of *HOXD9* as binding promoter regions of *HOXD9*. KTC, Korean Thyroid Cancer; TCGA-THCA, the Thyroid Carcinoma cohort from the Cancer Genome Atlas.